We report a symptomatic bilateral anterior uveitis (grade 2) with serous retinal detachment in a patient treated with nivolumab, an anti-PD-1 antibody approved for melanoma and lung cancer therapies. This evidence concerns the gene PDCD1 and retinal detachment.